A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.

Abstract

BACKGROUND & AIMS Osteoporosis is common in patients with inflammatory bowel disease (IBD). Corticosteroids induce a rapid and important bone loss. Clinical trials have shown oral bisphosphonates to effectively prevent steroid-induced bone loss. However, patients with IBD have been excluded from most of these studies because of potential digestive adverse events. Clodronate is a non-amino-bisphosphonate available in intravenous form without expected digestive (as oral bisphosphonates) or proinflammatory (as amine bisphosphonates) side effects. Our aim was to assess the efficacy of intravenous clodronate in preventing steroid-induced bone loss. METHODS A 12-month, double-blind, randomized, placebo-controlled trial was conducted in IBD patients beginning a steroid therapy. Sixty-seven patients (median disease duration, 38 mo; range, 1-240 mo) were randomized to receive one infusion per 3 months of either intravenous clodronate (900 mg, n = 33) or placebo. All the patients received calcium (1 g/day) and vitamin D (800 IU/day). The main outcome was the change in lumbar bone mineral density (BMD) between baseline and 1 year. Secondary outcomes included change in femoral neck BMD and adverse events. RESULTS After 1 year, there was no change in BMD in the clodronate group, neither at the spine (-0.2%, not significant) nor at the femoral neck (2.3%, NS). In contrast, there was a significant decrease in lumbar spine (-2.0%, P = .0018) and femoral neck (-1.7%, P = .045) BMD in the placebo group. Tolerance to treatment was good. CONCLUSIONS Intravenous clodronate is effective in the prevention of bone loss induced by steroids in patients with IBD.

Statistics

05010020072008200920102011201220132014201520162017
Citations per Year

203 Citations

Semantic Scholar estimates that this publication has 203 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Abitbol2007ADP, title={A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.}, author={Vered Abitbol and Karine Briot and Christian Roux and Carine Roy and Philippe Seksik and Antoine Charachon and Yoram Bouhnik and B Coffin and Matthieu Allez and Dominique Lamarque and Stanislas Chaussade}, journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association}, year={2007}, volume={5 10}, pages={1184-9} }